Daily Brief Archive: August 4, 2026 — U.S. & Hong Kong Stock Analysis

Free preview

U.S. Markets

  • Iran de-escalation sent crude down over 5%; risk appetite returned across the board
  • Dow hit a record 53,178; S&P 500 +1.48%, Nasdaq +2.1%
  • Microsoft added roughly $450B in one session — the largest single-day gain in US history
  • Morgan Stanley blessed AI capex; META +6%, GOOGL +4.9%
  • Apple bucked the tape at -1.78% as memory inflation bites margins and supply
  • AstraZeneca -6.88%: a rumored $400B megamerger was punished, not rewarded

Hong Kong

  • Hang Seng +0.48% back above 26,000; HS Tech +0.96%
  • Southbound net buying of HK$11.03B rotated back into platforms
  • Alibaba +7.01% to 125.2 on the 2.4T-parameter Qwen3.8 launch
  • WuXi AppTec lifted FY guidance to RMB58.5–60.5B; A/H shares ripped
  • CXO names rallied together: WuXi Bio +4.4%, Pharmaron +7.9%
  • Semis lagged all session; the Kingboard complex stayed pinned in oversold territory

Today's Watchlist

  • PLTR posted $0.41 EPS vs $0.28 est., revenue +92.8% after the close
  • SNDK reports FQ4 on 8/5, right after defending the $1,000 shelf
  • WuXi AppTec's H-shares spiked more than 14% intraday on 8/4
  • ATKR agreed to Prysmian's $95/share all-cash bid; the arb spread has narrowed
  • If AZN/BMY advances, antitrust review is the dominant variable
  • Memory inflation cuts both ways: a tailwind for MU/SNDK, a headwind for AAPL

Deep Dives (4 names)

Neutral
Score6/10RSI(14) 40.3RSI(7) 26.7P/E TTM 34.81-week -9.3%4-day drawdown -10%+

Technicals — It closed at $303.42, down 1.78%, falling on a day the Dow printed a record and the Nasdaq gained 2.1% — dismal relative strength. The four-session drawdown now exceeds 10%, taking price through the 20-day ($323.90) and 50-day ($309.52); the only structural support left is the 200-day at $278.24, still 8.3% below. RSI(7) at 26.7 is oversold while RSI(14) at 40.3 is not yet extreme — a technical bounce is due, but the trend has already broken.

Fundamentals — Q3 revenue of $109.4B rose 16% — the highest third quarter in company history — and EPS beat. But Q4 guidance of 9–11% growth implies roughly $113B against a $114.9B consensus. At 34.8x trailing earnings Apple is the most expensive name in this group, paired with 14.2% revenue growth and a 48.7% gross margin; in a rising memory-cost cycle that valuation offers no cushion. The Street's $328.01 average target implies just 8.1% upside, the lowest of any deep-dive name here.

News — Apple posted its worst single-day decline in more than a year, falling as much as 7.35% intraday on 8/3. The core issue: Cook stated plainly that component shortages, memory chips above all, will keep constraining iPhone, Mac and iPad production through the September quarter while raising hardware costs. Barclays and GF Securities followed with downgrades. The irony is that the same memory inflation crushing Apple is what has been lifting MU and SNDK — one cycle, and the buyer of chips pays for the seller's feast.

Short-term · 1–3 weeks
Neutral Sidelines

Closing the position this cycle — a defensive exit, not a stop-out on thesis. The long recorded on 7/29 has fallen from $340.08 to $303.42 as trend and fundamentals deteriorated together. Cook put a September-quarter timeline on the constraint; that's management guidance, not sentiment. RSI(7) at 26.7 will produce a bounce, but a bounce isn't a reversal, and 34.8x prices in no discount for a supply bottleneck. Reassess on the reaction at the $278.24 200-day.

Entry Sidelines; wait for a reaction at the 200-day near $278Stop —Target —
Long-term · months+
Neutral

The ecosystem and services moat is intact, and record Q3 revenue proves demand is healthy. But a rising memory-cost cycle will genuinely compress hardware margins, and 34.8x requires acceleration while guidance delivers the opposite.

  • If memory inflation runs into 2027, margin pressure exceeds current guidance
  • A 34.8x multiple is unsupported once growth decelerates toward 10%
  • Consensus upside of just 8.1% suggests the Street has already priced it in
Signal BacktestCumulative -2.96%price itself -7.35%0/1 closed trades wonprofitable since 07-09
  • 07-07Long$312.66 → closed $303.4208-04-2.96%
Community Voices
  • WSB · Mentions rose from 24 to 89 but drew only 228 upvotes; the chatter is complaint, not accumulation — retail is still waiting for a price that stops fallingOriginal ↗
Institutional Views
  • 华尔街共识 · 51 analysts average a $328.01 target, only 8.1% above spot, at a 1.50 rating that leans neutral — the narrowest upside among today's deep dives
  • Barclays · Downgraded on supply-chain challenges and margin headwindsSource ↗
Neutral
Score7/10RSI(14) 44.1P/E TTM 18.8EPS growth TTM +697%vs June high -33.9%DRAM ASP $1.17 (10-year peak)

Technicals — It closed at $829.50, up just 0.79%, essentially flat on a day the Nasdaq gained 2.1% — clearly weak relative strength. Price sits below the 20-day ($903.93) and 50-day ($966.80) while remaining far above the 200-day ($521.31): the intermediate trend is intact, the short-term trend is not. RSI(14) at 44.1 is neutral, with the stock down 11.0% on the week and 20.4% on the month. ATR of $88.83 equates to roughly 10.7% daily range, among the highest of any large-cap here. The $800 round number is both psychological and technical support; below it the next meaningful level is near $700.

Fundamentals — Trailing revenue is up 167%, EPS up 697%, on a 72.6% gross margin — against a multiple of just 18.8x. That is the classic shape of a cyclical top: exploding earnings inflate the denominator and flatter the apparent P/E. DRAM average selling prices have reached a ten-year peak of $1.17, with DDR5 16Gb spot up 0.72% and DDR4 16Gb up 0.57% on 8/3. Management says supply tightness persists beyond 2027 and has signed a five-year pricing lock. The debate isn't about how good today's cash flow is — it's whether the market will pay for the next leg of the cycle.

News — Micron fell as much as 3.5% to $794.59 in early trading on 8/3 after reports on Chinese rival ChangXin Memory (CXMT) revived supply-risk fears, before scraping out a +0.79% close. This is a continuation of the same thread that drove the CXMT Shanghai-listing panic in the last brief. The central tension is stark: spot prices are rising while the stock falls, meaning investors are discounting the durability of future pricing rather than the strength of present demand.

Short-term · 1–3 weeks
Neutral Sidelines

Maintaining last cycle's sidelines call: gaining only 0.79% on a broad-rally day is unambiguously negative relative strength when risk appetite is returning. An ATR of $88.83 means any entry absorbs 10%-scale intraday swings, while the CXMT capacity variable has neither a timeline nor hard data. The Street's 87.4% implied upside is seductive, but when analyst targets fight the tape, watch who is voting with actual money. Reassess only if $800 holds and price reclaims the 20-day at $903.93 on volume.

Entry Sidelines; wait for a decisive reaction at $800Stop —Target —
Long-term · months+
Neutral

Structural HBM and DRAM demand is real, and both spot pricing and the five-year lock support the tightness argument. But an 18.8x multiple rests on 697% EPS growth, and a low P/E near a cyclical earnings peak is a trap, not a discount.

  • The timing and scale of CXMT's capacity ramp remain entirely unknown
  • Once the cycle rolls, falling EPS turns 18.8x into 40x overnight
  • A 10.7% ATR makes position sizing punishing
Signal BacktestCumulative -26.77%price itself -19.64%0/2 closed trades wonprofitable since 07-10
  • 07-07Long$984.75 → closed $853.207-17-13.36%
  • 07-22Long$970.82 → closed $820.5307-29-15.48%
Community Voices
  • WSB · Mentions rocketed from 107 to 595 with 2,608 upvotes, holding the number one slot site-wide. The top of that leaderboard has never been a buy signal — it's a crowding alarmOriginal ↗
Institutional Views
  • 华尔街共识 · 56 analysts average a $1,554.51 target, a striking 87.4% above spot, at a 1.15 rating near strong buy — the gap between the Street and the tape is today's loudest signal
Neutral
Score8/10RSI(14) 43.2vs June high -45.3%YTD +427%ATR $198.21Earnings 8/5

Technicals — It closed at $1,288.03, up 6.03%. After bottoming at $1,015.89 on 7/29, the stock ripped 25.99% on 7/30 to $1,279.96, giving the $1,000 round number a live test it passed. Price remains below the 20-day ($1,486.57) and 50-day ($1,707.12) and sits 45.3% under the June high of $2,354.39, though far above the 200-day at $848.89. RSI(14) is a neutral 43.2. An ATR of $198.21 implies a 15.4% daily range — the most extreme volatility on the board, and any position must be sized as a wager rather than an investment.

Fundamentals — Trailing revenue is up 82.8% on a 56.0% gross margin, at a 44.8x multiple. Last quarter surging NAND prices plus AI-driven storage demand produced record revenue growth and materially better profitability, with the margin expansion showing effective cost pass-through. The stock is still up 427% year to date and 2,953.7% over one year — a base that forces any valuation discussion to start by acknowledging you are looking at a cyclical that has already run its primary advance.

News — SanDisk gained 6.03% on 8/3 (some feeds show +3.48%), extending its repair off the $1,000 support test as sentiment improved. The decisive event lies ahead: fiscal Q4 and full-year results land on 8/5, with the Street expecting strong year-over-year growth from AI and enterprise storage demand. From the $2,335 close on 6/25 to $1,015.89 on 7/29 the stock fell 56.49% — this print decides whether the bounce is a bottom or a way station.

Short-term · 1–3 weeks
Neutral Sidelines

Staying sidelined. The $1,000 shelf did hold and a 27% six-day bounce is genuinely impressive, but entering ahead of the 8/5 print is a pure event bet — with an ATR of $198.21, a 20% earnings gap is routine rather than tail risk. Wait for the print, a clear gap direction, and a reclaim of the 20-day at $1,486.57 before committing to a signal worth booking.

Entry Sidelines; no participation before the 8/5 printStop —Target —
Long-term · months+
Neutral

Margin expansion from NAND pricing and AI storage demand is real, and 44.8x against 82.8% revenue growth is not absurd. But a 2,953% one-year gain says the market has fully priced the upcycle; what remains is a race between delivery and giveback.

  • A 15.4% daily range makes long-term holding psychologically expensive
  • A peak in NAND pricing ends the margin-expansion story simultaneously
  • Still 45% below the June high; the downtrend has not been technically invalidated
Signal BacktestCumulative -31.04%price itself -26.19%0/1 closed trades wonprofitable since 07-24
  • 07-22Long$1,589.4 → closed $1,096.107-29-31.04%
Community Voices
  • WSB · Mentions rose from 58 to 221 for fifth place. Retail is loading up two days before the print — anyone entering here is betting on luck, not logicOriginal ↗
Institutional Views
  • 华尔街共识 · 30 analysts average a $2,363.65 target, roughly 83.5% above spot, at a 1.32 rating leaning strong buy
Neutral
Score7/10RSI(14) 32.3RSI(7) 22.5P/E TTM 23.9Relative volume 6.42xDividend yield 1.94%

Technicals — It closed at $157.97, down 6.88%, on 6.42x relative volume — a textbook news-driven volume break. Price sliced through the 20-day ($171.43), 50-day ($178.57) and 200-day ($184.31) in one session, leaving a complete bearish stack. RSI(7) at 22.5 is deeply oversold and RSI(14) at 32.3 is close behind, so a technical bounce is available — but the decline reflects a structural repricing on news rather than pure sentiment selling. The 52-week low at $141.77, 10.3% below, is the only clear support beneath.

Fundamentals — It trades at 23.9x trailing earnings with EPS up 17.0% but revenue growth of only 1.1% — the growth engine is visibly slowing, though a 73.9% gross margin remains excellent and a 1.94% yield offers a floor. The Street's $216.44 target implies 37.0% upside, among the widest discounts in today's deep dives. That gap says something specific: institutions believe the fundamentals are unchanged and only the deal-related uncertainty is new.

News — AstraZeneca plunged roughly 7.7% during Monday's US session on 8/3 (closing -6.88%) after the Financial Times reported merger talks with Bristol Myers Squibb on a deal worth close to $400B; Reuters confirmed preliminary contact through a person familiar, though neither company confirmed talks remain active. Investor pushback centered on three points: AstraZeneca's own organic growth and pipeline make the strategic logic questionable; antitrust risk is severe, since the combined oncology portfolio would likely be the industry's broadest; and integration would drag on the existing growth trajectory. Berenberg said shares would 'likely remain depressed.' Notably BMY rose 0.24% the same day — the would-be target was the calmer of the two.

Short-term · 1~3 weeks
Neutral Sidelines

RSI(7) at 22.5 is tempting and 37% implied upside is substantial, but this is not a technical mispricing — the mere existence of merger talks is an open variable that cannot be priced. Berenberg put it plainly: shares stay depressed while it's unresolved. Taking a direction before there are answers on deal structure, consideration, and the antitrust path means paying for someone else's uncertainty. Wait for a statement.

Entry Sidelines; wait for the talks to either advance concretely or be called offStop —Target —
Long-term · months+
Neutral

A 73.9% gross margin, a deep solid-tumor pipeline and a 1.94% yield make for a solid defensive asset at an undemanding 23.9x. But 1.1% revenue growth shows organic momentum is fading, and if a $400B merger proceeds the company's entire risk profile is rewritten.

  • If the deal advances, antitrust review could run years and force divestitures
  • Revenue growth of just 1.1% puts more pressure on pipeline delivery than the market assumes
  • Price is below all three moving averages; trend repair will take time
Community Voices
  • StockTwits · A 5.63 trending score with the debate fixed on whether a $400B deal is strategy or panic — for once retail asked 'why buy at all' before the institutions didOriginal ↗
Institutional Views
  • 华尔街共识 · 32 analysts average a $216.44 target, about 37.0% above spot, at a 1.33 rating leaning strong buy
  • Berenberg · Said shares will 'likely remain depressed' while the megadeal stays unresolvedSource ↗

Rapid Scan (15 names)

TickerCloseChangeScoreDirectionOne-line take
DTE logoDTEUS$141.72-0.11%5NeutralBelow both the 50-day at $147.25 and 200-day at $141.61 with RSI(7) at 27.5 — oversold but structurally broken. WSB mentions doubling to 80 is noise, not support. Closing the position.
NVDA logoNVDAUS$206.64+2.93%7NeutralUp 2.93%, notably light versus its index weight on a 2.1% Nasdaq day, with RSI at 53.1 sitting right on the 50-day at $205.84. The 52.1% consensus upside is tempting but direction is unresolved; sidelines.
AMD logoAMDUS$484.64+1.78%6NeutralUp 1.78% and trailing the sector, still below the 50-day at $512.95 after a 8.1% weekly decline. At 159x, there's no margin of safety amid semiconductor dispersion; sidelines.
SPCX logoSPCXUS$114.53+5.68%6NeutralUp 5.68% but down 28.3% on the month with RSI still soft at 38.3, no moving-average history and no verifiable financials. The 99.2% consensus upside cannot be independently checked; sidelines.
NBIS logoNBISUS$212.58+11.64%6NeutralUp 11.64% on the $1B-plus Reflection AI compute contract and neocloud sympathy, yet still below the 50-day at $224.11 with extreme volatility into the 8/12 print; sidelines.
RDDT logoRDDTUS$154.71+9.98%6NeutralUp 9.98% repairing the 20% post-earnings overreaction on 61% Q2 revenue growth and above-consensus Q3 guidance — but still below all three moving averages and down 20.3% on the month. A bounce is not a reversal; sidelines.
MCD logoMCDUS$265.23-2.00%5NeutralDown 2.0% as risk appetite returned, breaking the 50-day at $274.58 and 200-day at $300.31 and now just 1.6% off its 52-week low as defensives rotate out; sidelines.
GME logoGMEUS$19.06-12.25%4NeutralDown 12.25% on 13.18x volume with RSI(7) extremely oversold at 17.0 and just 2.7% above its low; on a meme stock that volume is the risk, not the opportunity; sidelines.
TGTX logoTGTXUS$46.17-11.26%4NeutralDown 11.26% on 3.13x volume with RSI(7) extremely oversold at 16.2 and price through every moving average — a sharp decline with no identified catalyst; sidelines.
SNAP logoSNAPUS$5.04+7.46%5NeutralUp 7.46% and 14.3% on the week with RSI at 60.8 reclaiming the 50-day at $4.99 — but still 18% below the 200-day at $6.15 with no fundamental improvement; sidelines.
VOYG logoVOYGUS$28.01+14.19%4NeutralUp 14.19% but down 17.1% on the month with RSI neutral at 48.4, still below every moving average; an unanchored space-concept move; sidelines.
SERV logoSERVUS$5.65+18.20%4NeutralUp 18.2% but down 13.9% on the month and 70% from its high with RSI neutral at 50.6; delivery robotics has no revenue at scale yet; sidelines.
CAT logoCATUS$830.03+1.87%5NeutralUp 1.87% but down 17.1% on the month with RSI weak at 39.6 and price below the 50-day at $919.23, as construction-equipment demand tracks fading infrastructure expectations; sidelines.
ZETA logoZETAUS$22.56+4.44%5NeutralUp 4.44% and 14.5% on the week with RSI at 59.3 above every moving average — a marketing-tech small cap riding risk appetite without standalone logic; sidelines.
TTD logoTTDUS$18.3+1.44%4NeutralUp 1.44% but 80% below its 52-week high and only 9.6% above its low with RSI at 47.1; the adtech valuation reset isn't finished; sidelines.
Stock Brief 2026-08-04: Daily U.S. & HK Market Analysis Archive · Quant Brief